<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309660</url>
  </required_header>
  <id_info>
    <org_study_id>PPAR2005</org_study_id>
    <nct_id>NCT00309660</nct_id>
  </id_info>
  <brief_title>Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <brief_summary>
    <textblock>
      Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine
      models of colitis. The aim of this study was to evaluate the effect of treatment with local
      PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with
      rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and
      after treatment by endoscopical and clinical activity score.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <completion_date>June 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endoscopic response</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Distal ulcerative colitis (Mayo Clinical Score &gt; 7)

          -  Age &gt; 18 years

          -  Written consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Severe ulcerative colitis

          -  Systemic treatment with steroids or azathioprin within the last 3 month

          -  Known liver or kidney disease

          -  Severe heart failure

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¸rn Brynskov, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept Gastroenterology C, Herlev University Hospital, 2730 Herlev, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gitte Pedersen</last_name>
    <phone>+ 45 44883418</phone>
    <email>gitped01@herlevhosp.kbhamt.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. Gastroenterology C, Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitte Pedersen, MD</last_name>
      <phone>+45 44883418</phone>
      <email>gitped01@herlevhosp.kbhamt.dk</email>
    </contact>
    <investigator>
      <last_name>Gitte Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>September 20, 2006</last_update_submitted>
  <last_update_submitted_qc>September 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2006</last_update_posted>
  <keyword>PPARgamma ligand</keyword>
  <keyword>Rosiglitazone</keyword>
  <keyword>Enema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

